2011
DOI: 10.1200/jco.2011.29.15_suppl.558
|View full text |Cite
|
Sign up to set email alerts
|

A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…For instance, the 70-gene GS can predict the disease outcome in patients with 1–3 positive lymph nodes 9 and can predict adjuvant chemotherapy response in early breast cancer 10 . The 21-gene GS has prognostic value in Asian populations with ER-positive and lymph node-negative breast cancer 11 , and can predict the response to neoadjuvant exemestane therapy in postmenopausal patients with the ER-positive breast cancer 12 .…”
Section: Introductionmentioning
confidence: 99%
“…For instance, the 70-gene GS can predict the disease outcome in patients with 1–3 positive lymph nodes 9 and can predict adjuvant chemotherapy response in early breast cancer 10 . The 21-gene GS has prognostic value in Asian populations with ER-positive and lymph node-negative breast cancer 11 , and can predict the response to neoadjuvant exemestane therapy in postmenopausal patients with the ER-positive breast cancer 12 .…”
Section: Introductionmentioning
confidence: 99%